Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol 100 mg - this is not an innocuous drug. it is not recommended for the treatment of asymptomatic hyperuricemia. allopurinol tablets reduce serum and urinary uric acid concentrations. its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see clinical pharmacology, contraindications, warnings, and precautions). allopurinol tablets are indicated in: - the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). - the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. treatment with allopurinol tablets should be discontinued when the potential for overproduction of uric acid is no longer present. - the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day i

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

blenheim pharmacal, inc. - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol 100 mg - this is not an innocuous drug. it is not recommended for the treatment of asymptomatic hyperuricemia. allopurinol tablets reduce serum and urinary uric acid concentrations. its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see clinical pharmacology, contraindications, warnings, and precautions). allopurinol tablets are indicated in: - the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). - the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. treatment with allopurinol tablets should be discontinued when the potential for overproduction of uric acid is no longer present. - the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day i

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

state of florida doh central pharmacy - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol 100 mg - this is not an innocuous drug. it is not recommended for the treatment of asymptomatic hyperuricemia. allopurinol tablets reduce serum and urinary uric acid concentrations. its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see clinical pharmacology, contraindications, warnings, and precautions). allopurinol tablets are indicated in: - the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). - the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. treatment with allopurinol tablets should be discontinued when the potential for overproduction of uric acid is no longer present. - the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day i

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

serb - primidone - oral tablet - 50mg

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

terumo australia pty ltd - 35440 - heart-lung bypass system module, detector, air/fluid level - level sensors pads are used to attach the level sensors to a hard shell reservoir to aid in blood level monitoring

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

terumo australia pty ltd - 35099 - heart-lung bypass system - the system is indicated for use for up to 6 hours in the extracorporeal circulation of blood for arterial perfusion, regional perfusion, and cardiopulmonary bypass procedures. the system incorporates both roller and centrifugal pumps as needed. the centrifugal pump is indicated for use in cardiopulmonary bypass procedures only. it is a highly configurable modular system with a distributed network architecture that allows the user to customise the number and types of system specific components or modules, which can be configurable, displayed and controlled from a central monitor.

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - primidone - oral tablet - 50mg

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

terumo australia pty ltd - 37238 - analyser, blood gas, extracorporeal - an instrument that provides continuous on-line monitoring of the extracorporeal partial pressure of oxygen and carbon dioxide, ph, potassium, oxygen saturation, haematocrit, haemoglobin and temperature. additional calculated values of base excess, bicarbonate, oxygen saturation, oxygen delivery and oxygen consumption may also be provided. parameters are displayed at either actual temperature or adjusted to 37?c. for documentation purposes, the systems integral printer provides a hard copy of displayed parameters.

Singapūra - angļu - HSA (Health Sciences Authority)

karl storz endoscopy singapore sales pte. ltd. - ear, nose & throat - intended to secure an open airway to aid the surgeon in viewing a patient’s upper airway and facilitate the introduction and removal of instruments and telescopes during endoscopic ent procedure.

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

lloyds pharmacy ltd - hexylresorcinol - lozenge - 2.4mg